Publication | Open Access
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
20
Citations
23
References
2023
Year
Atezo/Bev-TACE and LEN-TACE showed comparable efficacy and safety as first-line therapies for unresectable HCC patients.
| Year | Citations | |
|---|---|---|
Page 1
Page 1